New offering will support even more FM clients in their transition to renewable energy

LUXEMBOURG, March 11, 2025 /PRNewswire/ — Commercial property insurer FM today announced its insurance policy for renewable energy operation is now available to clients in Europe, the Middle East and Africa (EMEA), bringing decades of power generation research and engineering expertise to this growing market.

FM’s new offering will help EMEA clients in their transition to alternative energy through research and innovation as well as support the overall advancement of the renewable energy industry. The growth of the renewable energy sector is expected to accelerate in response to climate emission reduction targets, even as the industry faces challenges associated with new technologies and increased vulnerability to loss events, particularly climate-related hazards. The launch of FM’s renewable energy operational policy in EMEA will help FM’s clients navigate this rapidly evolving risk landscape.

“We are thrilled to expand our renewable energy services and solutions to more FM clients around the world,” said Doug Patterson, senior vice president, Forest Products and FM Renewable Energy at FM. “With FM’s research capabilities and engineering-based approach to risk mitigation and protecting our clients’ purpose, we are in a unique position to help our clients in their energy transition and take a leading role in supporting the renewable energy industry as it evolves.”

Last year FM announced the formation of FM Renewable Energy, which focuses on research, standards development and loss-prevention engineering around utility-scale ground mounted solar, onshore wind power and battery energy storage systems (BESS). For 70 years, FM has served power generators in a variety of energy sectors, including hydropower, biomass and waste-to-energy. FM Renewable Energy helps leaders design, build and operate resilient and reliable energy projects – and protect them over the long term.

Renewable energy projects face a wide range of risks, from windstorms and hail to lightning and equipment breakdown. FM offers a suite of products and services to help protect renewable energy operations, including climate change impact reports, business risk consulting services and research-based data sheets.

About FM

Established nearly two centuries ago, FM is a leading mutual insurance company whose capital, scientific research capability and engineering expertise are solely dedicated to property risk management and the resilience of its policyholder-owners. These owners, who share the belief that the majority of property loss is preventable, represent many of the world’s largest organizations, including one of every four Fortune 500 companies. They work with FM to better understand the hazards that can impact their business continuity to make cost-effective risk management decisions, combining property loss prevention with insurance protection.

Logo – https://mma.prnewswire.com/media/2462901/FM_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/fm-renewable-energy-launches-in-emea-302397686.html

Advertisement

LONDON, TALLINN, Estonia and GIBRALTAR , March 11, 2025 /PRNewswire/ — Orbital, a multi-licensed provider of stablecoin and traditional payment solutions, announces the integration of The Open Network (TON) blockchain into its Crypto Payment Gateway, enabling merchants to expand into emerging markets.

TON is a high-performance layer-1 blockchain designed for fast, low-cost transactions. Its deep integration with Telegram has fueled rapid adoption, particularly in emerging markets such as Turkey, Brazil and Indonesia.

“At Orbital, we continuously listen to our clients while shaping the future of global payments. Our mission is to make payments more accessible and secure so businesses can focus on growth. By integrating TON Blockchain for stablecoin payments, we’re reinforcing our commitment to building a powerful, global payments platform—one that unifies stablecoin speed with traditional finance to move money smarter.”– said Chris Mason, CEO of Orbital.

Orbital’s Crypto Payment Gateway allows businesses to accept crypto payments across six currencies, including two major stablecoins, on five blockchains. Merchants can choose from several options to accept crypto payments, including Embedded Payments Pages, a WooCommerce Plugin, or fully custom solutions using the Orbital API.

Once payments are accepted, they can be used within Orbital’s all-in-one payment platform, which also allows businesses to receive assets in major stablecoins, 11 traditional currencies, and 60+ exotic currencies, via SWIFT, Faster Payments, CHAPS, and Fedwire payment systems. Businesses can benefit from global accounts in both stablecoins and traditional currencies, exchange assets, initiate payouts, and handle tailored requests via the OTC desk, creating a smarter way to move money globally and scale efficiently.

Why Supporting TON Blockchain for Stablecoin Payments Matters

• Growing adoption – TON now has 2.7 million holders of the most widely used stablecoin on the network, with a total supply of $1.43 billion (Tonscan.org, Feb 2025).
• Lower transaction costs – Stablecoin payments on TON are more cost-effective compared to Ethereum and TRON (Gasfeesnow.com).
• Engaging with Telegram’s 950M+ user base unlocks significant distribution opportunities.

While stablecoins offer significant efficiencies, they carry risks related to issuer solvency, reserve adequacy, and evolving regulatory frameworks. Businesses should assess these factors when considering stablecoin adoption.

For more details on TON Blockchain support and how it benefits business, visit Orbital’s Website and request a call with our team.

Media Contact

Advertisement

Andrea Pearson
Head of Marketing & Corporate Communications, Orbital
[email protected] www.getorbital.com

About Orbital

Orbital is an award-winning global payments platform with over 8 years of experience in orchestrating secure and seamless stablecoin and traditional payments for businesses globally. Headquartered in London, Tallinn, and Gibraltar, Orbital is licensed as an FCA-authorized payment institution in the UK, an EMI and DLT Provider in Gibraltar, a VASP in Estonia, and holds VQF SRO membership in Switzerland.

Orbital equips B2B and B2C businesses with an all-in-one platform that offers named vIBANs, Stablecoin Wallets, and the ability to pay-in, payout, and exchange across all major stablecoins, traditional currencies, and over 80 exotic currencies, interchangeably.

Orbital’s multi-jurisdictional licensing framework, combined with compliance with international security standards including SOC 2 Type 2, ISO 27001:2022, CSA TPC, and Cyber Essentials Plus, enables the platform to seamlessly unify both stablecoin and traditional currency payments on a global scale.

Important: This communication is for informational purposes only and does not constitute financial or investment advice. It is intended exclusively for eligible corporate clients outside the UK and high net worth companies. Cryptocurrencies are highly volatile and carry significant risks, including potential total loss. Past performance is not a guarantee of future results. Seek independent professional advice before investing. Crypto-asset products and services mentioned here are not authorised or regulated by the UK FCA. These investments may lack the protections of FCA-regulated products.

About The Open Network (TON)
The Open Network (TON) is a global, decentralized blockchain community focused on putting crypto in every pocket. By building the Web3 ecosystem in Telegram Messenger, TON’s vision is to empower 500 million users to own their digital identity, data, and assets by 2028. Learn more at https://ton.org/

Photo: https://mma.prnewswire.com/media/2636715/Orbital.jpg
Logo:  https://mma.prnewswire.com/media/2636714/Orbital_Logo.jpg

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/orbital-now-supports-stablecoin-payments-on-ton-blockchain-302395716.html

• Financing led by existing investors Fountain Healthcare Partners and Panakès Partners;
• Neuromod will use funds to accelerate commercialisation in the USA and Europe.

DUBLIN, March 11, 2025 /PRNewswire/ — Neuromod Devices Ltd. (Neuromod), an Irish medical device company specialising in tinnitus, has successfully closed a €10 million equity financing to expand the availability of its tinnitus treatment device, Lenire.

Oversubscribed Financing to Drive Commercialisation

Neuromod has raised €10 million of equity in an expansion of its Series B fundraisings. The financing was oversubscribed and was led by existing investors Fountain Healthcare Partners and Panakès Partners, backing Neuromod’s mission to advance tinnitus care for patients globally.

Neuromod has been making Lenire available through audiology and ENT practices throughout the USA and Europe. Proceeds from the financing will be used to meet demand for Lenire through sustainable commercial expansion in the USA and Europe and expand on existing opportunities in the US Department of Veteran Affairs (USVA).

Following FDA approval in March 2023, more than 100 clinics throughout the USA now treat tinnitus patients with Lenire. Availability of Lenire has also expanded in Europe with clinics in 14 countries now using the device. In the last 6 months, the number of clinics in the UK trained to use Lenire has doubled, and it is available to patients in Sweden for the first time.

In June 2024, Neuromod was awarded a Federal Supply Schedule 65 II Medical Equipment and Supply Contract from the US Government, making Lenire a treatment option for the 2.9 million US Veterans living with tinnitus^v through the USVA. 35 USVA facilities have been trained to provide treatment with Lenire with more scheduled for training in 2025.

Real-World Evidence – Substantial Momentum

Positive results for tinnitus patients treated with Lenire in real-world settings at independent USA-based clinics have been compiled with a base of over 1,500 patients that continues to grow. In what will be the first of a series of planned real-world evidence publications, results from Alaska Hearing & Tinnitus Center showed that 91.5% of 220 patients reported clinically significant improvement in their tinnitus^vi. This data is consistent with, and in many instances outperforms, data from Lenire’s large-scale clinical trials.

These results followed the publication of Lenire’s pivotal controlled clinical trial results, which led to US FDA approval and featured as the cover-story in peer-reviewed journal, Nature Communications^iv. This article is in the 99th percentile of more than 250,000 tracked Nature articles.

Advertisement

Comments

Commenting on the news, Dr. Ross O’Neill PhD, Founder & CEO of Neuromod, said, “We are delighted to announce an oversubscribed financing at a pivotal time when we are driving forward with our mission of making Neuromod the category creator for tinnitus globally.”

“Tinnitus is the largest unmet need in hearing healthcare globally and is the number one service-connected disability among US veterans and military personnel. I am proud of the progress Neuromod is making to deliver our market-surpassing treatment to as many tinnitus patients as possible while enabling care providers’ expertise to be commercially rewarded. I am also grateful for the continued support of our investors who share our vision of advancing tinnitus care globally,” Dr. O’Neill continued.

Dr. Manus Rogan, Chairman of Neuromod and Managing Partner of Fountain Healthcare Partners, commented, “Recent results from tinnitus patients using Lenire in the real-world show that it represents a new standard of care for tinnitus. The successful closing of this financing ensures more patients will get access to this standard of care as quickly as possible.”

Alessio Beverina, Managing Partner of Panakès Partners, said, “Panakès is pleased with the progress of Neuromod since our investment, with significant clinical trial, FDA approval, real-world evidence, and commercial success in both Europe and the USA; and it is proud to continue supporting Neuromod’s work to bring a new standard of care to a historically underserved patient population.”

Emily E. McMahan, Owner of Alaska Hearing and Tinnitus Center and author of the clinic’s Real World Evidence Paper, said, “Impressive clinical trial results for Lenire led me to early adoption of the landmark tinnitus treatment technology.”

“In my clinic, and my colleagues’ clinics, we are seeing results that are superior to clinical trial results,” Dr. McMahan continued.

About Neuromod Devices Ltd

Founded in 2010, Neuromod Devices Ltd. is a medical technology company headquartered in Dublin, Ireland. Neuromod specialises in the design, development, and commercialisation of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder. For more information visit www.neuromoddevices.com.

About Tinnitus

Advertisement

Tinnitus, commonly known as ‘ringing in the ears’, is a complex neurological condition that causes a perception of sound when there is no external source. Tinnitus affects an estimated 15% of the global adult populationⁱ.

The management of tinnitus poses significant burden on healthcare systems. A 2021 study estimated the socioeconomic costs of tinnitus in Germany at €21.9 billion per annum^vii. In the USA it’s estimated the Veterans Benefits Administration paid out approximately $5.8 billion through its Veterans Compensation benefits program for tinnitus in 2023^v. The American Tinnitus Association, the leading advocacy body in the USA for people living with the condition, has recently revised its estimate that 50 million Americans live with tinnitus upward to 70 million^viii.

About Lenire

Lenire is the first non-invasive bimodal neuromodulation tinnitus treatment device shown to soothe and relieve tinnitus in a large-scale clinical trial. Lenire works by delivering mild electrical pulses to the tongue, through an intra-oral component called the ‘Tonguetip®’, combined with auditory stimulation through headphones. This combination drives changes in the brain to treat tinnitus. To date, the device has been used in large-scale clinical trials with over 700 patients^ii,iii,iv.

Lenire has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional in Europe and has received a De Novo grant of approval by the US FDA. Further details about Lenire including a list of providers can be found at www.lenire.com.

Connect with Neuromod Devices Ltd

LinkedIn: linkedin.com/neuromod
X: x.com/NeuromodDevices
Facebook: facebook.com/neuromoddevices/ 
Website: www.neuromoddevices.com

References & Notes

(i) Baguely et al., Tinnitus, The Lancet (2013), sciencedirect.com/science/article/pii/S0140673613601427
(ii) Conlon et al., Sci. Transl. Med. 12, eabb2830 (2020)
(iii) Conlon et al., Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial, Sci Rep, doi.org/10.1038/s41598-022-13875-x (2022)
(iv) Boedts M, B. A., Khoo G, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a controlled pivotal trial. Nature communications (2024)
(v) US VA Benefits Report Fiscal Year 2023: https://www.benefits.va.gov/REPORTS/abr/
(vi) McMahan, E.E. and Lim, H.H., 2024. Effectiveness of bimodal neuromodulation for tinnitus treatment in a real-world clinical setting in United States: A retrospective chart review. medRxiv., pp.2024-08; doi: https://doi.org/10.1101/2024.08.22.24312175 [preprint]
(vii) Tziridis K, Friedrich J, Brüeggemann P, Mazurek B, Schulze H. Estimation of Tinnitus-Related Socioeconomic Costs in Germany. Int J Environ Res Public Health. 2022 Aug 22;19(16):10455. doi: 10.3390/ijerph191610455. PMID: 36012089; PMCID: PMC9407899
(viii) https://www.linkedin.com/posts/patrickalynch_tinnitus-activity-7270503831304654848-VbWN/

Photo: https://mma.prnewswire.com/media/2638098/Neuromod_Dr_Ross_ONeill.jpg

Advertisement

View original content:https://www.prnewswire.co.uk/news-releases/neuromod-closes-10-million-financing-to-accelerate-commercialisation-302398184.html